( ritis is a progressive systemic autoim...)Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis,Health

ritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain, and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin and osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50% of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 2.1 million people affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.

    (1) ACR20, ACR50 and ACR70 represent the percentage of reduction (20%, 50%

        or 70%) in certain RA sym
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid
Arthritis Compared to a Current Standard of Care
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin
Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by
Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who
Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in
Development of CF502 Will Be Presented at the Annual European
Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human
Trial of Third Generation RIMA Antidepressant
7. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone